Log in with your email address username.


[Correspondence] Concerns about cardiotoxicity in the HERA trial – Authors’ reply

We would like to thank Antonin Levy and colleagues for their interest in our Article reporting the 11-year outcome data from the HERceptin Adjuvant (HERA) trial,1 and their expressed concern that we might not have recorded all long-term cardiac consequences of treatment for early breast cancer, specifically, some that could be secondary to the use of radiotherapy.